| Shahryar Yadegar, MD | |
|
18399 Ventura Blvd, Suite 245, Tarzana, CA 91356-4233 | |
| (818) 609-7536 | |
| (818) 344-9670 |
| Full Name | Shahryar Yadegar |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 29 Years |
| Location | 18399 Ventura Blvd, Tarzana, California |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174546493 | NPI | - | NPPES |
| 00A614758 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | A61475 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Tarzana Medical Center | Tarzana, CA | Hospital |
| Cedars-sinai Medical Center | Los angeles, CA | Hospital |
| Sherman Oaks Health & Rehab | Sherman oaks, CA | Nursing home |
| Entity Name | Pulmonary Professionals A Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861414716 PECOS PAC ID: 1052362860 Enrollment ID: O20060907000565 |
News Archive
"This is a totally new approach to cancer therapy," says Professor Patrick Gunning of the Department of Chemical and Physical Sciences. "Everything prior to this has targeted functionally relevant binding sites. Our approach inhibits the mobility of cancer-promoting proteins within cells-essentially, it's like molecularly targeted glue."
An investigational device that deflects debris away from the brain during transcatheter aortic valve replacement seems to improve in-hospital safety outcomes and cognitive scores at discharge, according to preliminary findings from a small randomized study presented at the American College of Cardiology's 64th Annual Scientific Session.
NGM Biopharmaceuticals, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM's enteroendocrine cell program for the treatment of type 2 diabetes and obesity.
An interesting new study available as a preprint on the medRxiv* server suggests that vagally-mediated heart rate variability (vmHRV) is a physiological marker of resilience to stress by indicating how well an individual handles the emotions when faced with changes in the surroundings.
› Verified 1 days ago
| Entity Name | Pulmonary Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538392543 PECOS PAC ID: 0345388989 Enrollment ID: O20091119000037 |
News Archive
"This is a totally new approach to cancer therapy," says Professor Patrick Gunning of the Department of Chemical and Physical Sciences. "Everything prior to this has targeted functionally relevant binding sites. Our approach inhibits the mobility of cancer-promoting proteins within cells-essentially, it's like molecularly targeted glue."
An investigational device that deflects debris away from the brain during transcatheter aortic valve replacement seems to improve in-hospital safety outcomes and cognitive scores at discharge, according to preliminary findings from a small randomized study presented at the American College of Cardiology's 64th Annual Scientific Session.
NGM Biopharmaceuticals, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM's enteroendocrine cell program for the treatment of type 2 diabetes and obesity.
An interesting new study available as a preprint on the medRxiv* server suggests that vagally-mediated heart rate variability (vmHRV) is a physiological marker of resilience to stress by indicating how well an individual handles the emotions when faced with changes in the surroundings.
› Verified 1 days ago
| Entity Name | Tarzana Hospitalist Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255564944 PECOS PAC ID: 7810037868 Enrollment ID: O20091222000707 |
News Archive
"This is a totally new approach to cancer therapy," says Professor Patrick Gunning of the Department of Chemical and Physical Sciences. "Everything prior to this has targeted functionally relevant binding sites. Our approach inhibits the mobility of cancer-promoting proteins within cells-essentially, it's like molecularly targeted glue."
An investigational device that deflects debris away from the brain during transcatheter aortic valve replacement seems to improve in-hospital safety outcomes and cognitive scores at discharge, according to preliminary findings from a small randomized study presented at the American College of Cardiology's 64th Annual Scientific Session.
NGM Biopharmaceuticals, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM's enteroendocrine cell program for the treatment of type 2 diabetes and obesity.
An interesting new study available as a preprint on the medRxiv* server suggests that vagally-mediated heart rate variability (vmHRV) is a physiological marker of resilience to stress by indicating how well an individual handles the emotions when faced with changes in the surroundings.
› Verified 1 days ago
| Entity Name | Cedars Primary Care Apmc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396115853 PECOS PAC ID: 6204134406 Enrollment ID: O20160420001770 |
News Archive
"This is a totally new approach to cancer therapy," says Professor Patrick Gunning of the Department of Chemical and Physical Sciences. "Everything prior to this has targeted functionally relevant binding sites. Our approach inhibits the mobility of cancer-promoting proteins within cells-essentially, it's like molecularly targeted glue."
An investigational device that deflects debris away from the brain during transcatheter aortic valve replacement seems to improve in-hospital safety outcomes and cognitive scores at discharge, according to preliminary findings from a small randomized study presented at the American College of Cardiology's 64th Annual Scientific Session.
NGM Biopharmaceuticals, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM's enteroendocrine cell program for the treatment of type 2 diabetes and obesity.
An interesting new study available as a preprint on the medRxiv* server suggests that vagally-mediated heart rate variability (vmHRV) is a physiological marker of resilience to stress by indicating how well an individual handles the emotions when faced with changes in the surroundings.
› Verified 1 days ago
| Entity Name | Evolve Concierge |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578225140 PECOS PAC ID: 9234523895 Enrollment ID: O20220224000109 |
News Archive
"This is a totally new approach to cancer therapy," says Professor Patrick Gunning of the Department of Chemical and Physical Sciences. "Everything prior to this has targeted functionally relevant binding sites. Our approach inhibits the mobility of cancer-promoting proteins within cells-essentially, it's like molecularly targeted glue."
An investigational device that deflects debris away from the brain during transcatheter aortic valve replacement seems to improve in-hospital safety outcomes and cognitive scores at discharge, according to preliminary findings from a small randomized study presented at the American College of Cardiology's 64th Annual Scientific Session.
NGM Biopharmaceuticals, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM's enteroendocrine cell program for the treatment of type 2 diabetes and obesity.
An interesting new study available as a preprint on the medRxiv* server suggests that vagally-mediated heart rate variability (vmHRV) is a physiological marker of resilience to stress by indicating how well an individual handles the emotions when faced with changes in the surroundings.
› Verified 1 days ago
| Entity Name | West Valley Intensivist Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518418219 PECOS PAC ID: 4183995574 Enrollment ID: O20230823002751 |
News Archive
"This is a totally new approach to cancer therapy," says Professor Patrick Gunning of the Department of Chemical and Physical Sciences. "Everything prior to this has targeted functionally relevant binding sites. Our approach inhibits the mobility of cancer-promoting proteins within cells-essentially, it's like molecularly targeted glue."
An investigational device that deflects debris away from the brain during transcatheter aortic valve replacement seems to improve in-hospital safety outcomes and cognitive scores at discharge, according to preliminary findings from a small randomized study presented at the American College of Cardiology's 64th Annual Scientific Session.
NGM Biopharmaceuticals, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM's enteroendocrine cell program for the treatment of type 2 diabetes and obesity.
An interesting new study available as a preprint on the medRxiv* server suggests that vagally-mediated heart rate variability (vmHRV) is a physiological marker of resilience to stress by indicating how well an individual handles the emotions when faced with changes in the surroundings.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shahryar Yadegar, MD Po Box 1133, Studio City, CA 91614-0133 Ph: (310) 914-9105 | Shahryar Yadegar, MD 18399 Ventura Blvd, Suite 245, Tarzana, CA 91356-4233 Ph: (818) 609-7536 |
News Archive
"This is a totally new approach to cancer therapy," says Professor Patrick Gunning of the Department of Chemical and Physical Sciences. "Everything prior to this has targeted functionally relevant binding sites. Our approach inhibits the mobility of cancer-promoting proteins within cells-essentially, it's like molecularly targeted glue."
An investigational device that deflects debris away from the brain during transcatheter aortic valve replacement seems to improve in-hospital safety outcomes and cognitive scores at discharge, according to preliminary findings from a small randomized study presented at the American College of Cardiology's 64th Annual Scientific Session.
NGM Biopharmaceuticals, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM's enteroendocrine cell program for the treatment of type 2 diabetes and obesity.
An interesting new study available as a preprint on the medRxiv* server suggests that vagally-mediated heart rate variability (vmHRV) is a physiological marker of resilience to stress by indicating how well an individual handles the emotions when faced with changes in the surroundings.
› Verified 1 days ago
Ryan Matthew Ponec, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 18133 Ventura Blvd Ste 300, Tarzana, CA 91356 Phone: 818-981-3818 | |
Dr. Jeffrey Philip Salberg, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 18370 Burbank Blvd, Ste 601, Tarzana, CA 91356 Phone: 818-996-5700 Fax: 818-996-1649 | |
Dr. Jeffrey Work, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 18370 Burbank Blvd, Suite 707, Tarzana, CA 91356 Phone: 818-345-5580 Fax: 818-774-0458 | |
Alan Fozailoff, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 18370 Burbank Blvd, Suite 211, Tarzana, CA 91356 Phone: 818-334-5750 Fax: 951-272-9924 | |
Dr. Yehuda Handelsman, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 18372 Clark St, Suite 212, Tarzana, CA 91356 Phone: 818-708-9942 Fax: 818-708-0154 | |
Dr. Richard C Wong, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 18370 Burbank Blvd, Suite 707, Tarzana, CA 91356 Phone: 818-345-5580 Fax: 818-774-0458 | |
Dr. Mark L Geller, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 18133 Ventura Blvd, Suite 204, Tarzana, CA 91356 Phone: 818-466-7700 Fax: 818-996-1649 |